Harbour BioMed and Evinova China announce strategic collaboration to accelerate AI-enabled drug development – BioSpectrum Asia
November 10, 2025 | Monday | News
image credit- shutterstock
Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, have announced a strategic collaboration in artificial intelligence (AI).
Dr Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, stated, “Harbour BioMed has built a robust and differentiated product pipeline based on our industry-leading Harbour Mice® technology platform. Through this collaboration, we look forward to applying AI to improving clinical study efficiency and accelerating the delivery of innovative therapies to patients around the world.”
Nate Zhang, General Manager of Evinova China, stated, “Evinova leverages the digital transformation insights of top global pharmaceutical companies to design our AI-powered clinical development solutions and digital strategy consulting services, so that we can accelerate the delivery of better health outcomes. To realize our mission, Evinova China needs to partner with innovative companies like Harbour BioMed, which are rooted in China while harboring global ambitions. Together, through our world-class AI technology platforms and deep therapeutic expertise, we can help take China-originated breakthrough assets from the laboratory to the world.”
Is Private Sector Fueling APAC Vax Demand?
MM Activ Singapore Pte Ltd
1 North Bridge Road,
#08-08 High Street Centre,
Singapore 179094
communications@biospectrumasia.com
+65 90150305
Copyright 2025 MM Activ Singapore Pte Ltd. All Rights Reserved.
source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.
